冠昊生物科技股份有限公司2024年年度报告摘要

Core Viewpoint - The company is focusing on innovation and market expansion in response to the evolving healthcare landscape, particularly in the fields of biomaterials, pharmaceuticals, and cell therapy, while ensuring sustainable development and internal governance optimization [2][6]. Company Overview - The company is actively engaged in the development of innovative products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of growth [2]. - The company has established a leading technology platform for animal-derived medical biomaterials, participating in over twenty national and local scientific projects [3]. Business Segments Biomaterials - The company has developed a series of regenerative medical materials that exhibit good tissue compatibility and promote tissue growth, with several products already on the market for various medical applications [3][4]. - Key products include biological dura (spinal) patches and sterile biological dressings, which are applicable in neurosurgery, thoracic surgery, dermatology, orthopedics, and more [4]. Pharmaceuticals - The company’s pharmaceutical research has yielded Baimuode, a first-in-class drug for treating inflammatory and autoimmune diseases, which has been included in the national medical insurance directory [4]. - Baimuode has potential applications in several important disease areas, with ongoing clinical trials for atopic dermatitis [4]. Cell Therapy - The company is enhancing its capabilities in the preparation of immune and stem cells, focusing on clinical efficacy and safety evaluations [5]. - Current projects include autologous cartilage cell transplantation and immune cell storage technology, aimed at treating joint cartilage defects and cancer, respectively [5]. Financial Data - The company has not required retrospective adjustments or restatements of previous financial data, indicating stable financial reporting practices [7]. - There are no significant discrepancies between the reported financial indicators and previously disclosed quarterly or semi-annual reports [7]. Future Outlook - The company plans to continue focusing on its three core business areas while enhancing innovation and market development efforts to navigate internal and external challenges [6].